EP Patent

EP1185277A1 — Methods for modulating fxr receptor activity

Assigned to Allergan Inc · Expires 2002-03-13 · 24y expired

What this patent protects

Methods for modulating the activity of the mammalian FXR receptor. The methods include methods of treating a hyper- or hypocholesterolemic mammal comprising contacting the mammal with synthetic compounds having FXR receptor activity.

USPTO Abstract

Methods for modulating the activity of the mammalian FXR receptor. The methods include methods of treating a hyper- or hypocholesterolemic mammal comprising contacting the mammal with synthetic compounds having FXR receptor activity.

Drugs covered by this patent

Patent Metadata

Patent number
EP1185277A1
Jurisdiction
EP
Classification
—
Expires
2002-03-13
Drug substance claim
No
Drug product claim
No
Assignee
Allergan Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.